Epigenetic regulation of spinal cord gene expression controls Opioid-Induced Hyperalgesia

Molecular Pain

J David Clark¹  Peyman Sahbaie¹  Xiao-You Shi¹  Yuan Sun¹  De-Yong Liang¹ 

[1] Anesthesiology Service, Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave (112-A), Palo Alto, CA 94304, USA

关键词: BDNF and dynorphin;    Opioid induced hyperalgesia;    Histone acetylation;    Epigenetics;   

Others  :  1138496
DOI  :  10.1186/1744-8069-10-59

 received in 2014-02-28, accepted in 2014-09-04,  发布年份 2014

【 摘 要 】

Background

The long term use of opioids for the treatment of pain leads to a group of maladaptations which includes opioid-induced hyperalgesia (OIH). OIH typically resolves within few days after cessation of morphine treatment in mice but is prolonged for weeks if histone deacetylase (HDAC) activity is inhibited during opioid treatment. The present work seeks to identify gene targets supporting the epigenetic effects responsible for OIH prolongation.

Results

Mice were treated with morphine according to an ascending dose protocol. Some mice also received the selective HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) additionally. Chronic morphine treatment with simultaneous HDAC inhibition enhanced OIH, and several spinal cord genes were up-regulated. The expression of Bdnf (Brain-derived neurotrophic factor) and Pdyn (Prodynorphin) were most closely related to the observed behavioral changes. ChIP (Chromatin immuoprecipation) assays demonstrated that promoter regions of Pdyn and Bdnf were strongly associated with aceH3K9 (Acetylated histone H3 Lysine9) after morphine and SAHA treatment. Furthermore, morphine treatment caused an increase in spinal BDNF and dynorphin levels, and these levels were further increased in SAHA treated mice. The selective TrkB (tropomyosin-receptor-kinase) antagonist ANA-12 reduced OIH when given one or seven days after cessation of morphine. Treatment with the selective kappa opioid receptor antagonist nor-BNI also reduced established OIH. The co-administration of either receptor antagonist agent daily with morphine resulted in attenuation of hyperalgesia present one day after cessation of treatment. Additionally, repeated morphine exposure induced a rise in BDNF expression that was associated with an increased number of BDNF⁺ cells in the spinal cord dorsal horn, showing strong co-localization with aceH3K9 in neuronal cells. Lastly, spinal application of low dose BDNF or Dynorphin A after resolution of OIH produced mechanical hypersensitivity, with no effect in controls.

Conclusions

The present study identified two genes whose expression is regulated by epigenetic mechanisms during morphine exposure. Treatments aimed at preventing the acetylation of histones or blocking BDNF and dynorphin signaling may reduce OIH and improve long-term pain using opioids.

【 授权许可】

   
2014 Liang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R: Opioid complications and side effects. Pain Physician 2008, 11(2 Suppl):S105-S120.
• [2]Chapman CR, Lipschitz DL, Angst MS, Chou R, Denisco RC, Donaldson GW, Fine PG, Foley KM, Gallagher RM, Gilson AM, Haddox JD, Horn SD, Inturrisi CE, Jick SS, Lipman AG, Loeser JD, Noble M, Porter L, Rowbotham MC, Schoelles KM, Turk DC, Volinn E, Von Korff MR, Webster LR, Weisner CM: Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain 2010, 11(9):807-829.
• [3]Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ: Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 2011, 14(2):E133-E156.
• [4]Paulozzi L, Baldwin G, Franklin G, Gil Kerlikowske R, Jones CM, Ghiya N: CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012, 61(1):10-13.
• [5]Chen L, Malarick C, Seefeld L, Wang S, Houghton M, Mao J: Altered quantitative sensory testing outcome in subjects with opioid therapy. Pain 2009, 143(1–2):65-70.
• [6]Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, Brummett C, Mao J: The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med 2008, 33(3):199-206.
• [7]Compton P, Canamar CP, Hillhouse M, Ling W: Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy. J Pain 2012, 13(4):401-409.
• [8]Patanwala AE, Jarzyna DL, Miller MD, Erstad BL: Comparison of opioid requirements and analgesic response in opioid-tolerant versus opioid-naive patients after total knee arthroplasty. Pharmacotherapy 2008, 28(12):1453-1460.
• [9]Rapp SE, Ready LB, Nessly ML: Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain 1995, 61(2):195-201.
• [10]Angst MS, Clark JD: Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006, 104(3):570-587.
• [11]Chu LF, Angst MS, Clark D: Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008, 24(6):479-496.
• [12]Low Y, Clarke CF, Huh BK: Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med J 2012, 53(5):357-360.
• [13]Bird A: Perceptions of epigenetics. Nature 2007, 447(7143):396-398.
• [14]Doehring A, Geisslinger G, Lotsch J: Epigenetics in pain and analgesia: an imminent research field. Eur J Pain 2011, 15(1):11-16.
• [15]Riddihough G, Zahn LM: Epigenetics. what is epigenetics? Introduction. Science 2010, 330(6004):611.
• [16]Wong CC, Mill J, Fernandes C: Drugs and addiction: an introduction to epigenetics. Addiction 2011, 106(3):480-489.
• [17]Wang L, Lv Z, Hu Z, Sheng J, Hui B, Sun J, Ma L: Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement. Neuropsychopharmacology 2010, 35(4):913-928.
• [18]Liang DY, Li X, Clark JD: Epigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice. J Pain 2013, 14(1):36-47.
• [19]Liang DY, Guo T, Liao G, Kingery WS, Peltz G, Clark JD: Chronic pain and genetic background interact and influence opioid analgesia, tolerance, and physical dependence. Pain 2006, 121(3):232-240.
• [20]Liang DY, Li X, Clark JD: 5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology 2011, 114(5):1180-1189.
• [21]Liang DY, Liao G, Lighthall GK, Peltz G, Clark DJ: Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogenet Genomics 2006, 16(11):825-835.
• [22]Liang DY, Liao G, Wang J, Usuka J, Guo Y, Peltz G, Clark JD: A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 2006, 104(5):1054-1062.
• [23]Liang D, Li X, Clark JD: Increased expression of Ca2+/calmodulin-dependent protein kinase II alpha during chronic morphine exposure. Neuroscience 2004, 123(3):769-775.
• [24]Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T: Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 2007, 85(3):525-535.
• [25]Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M, Persson H: Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 1993, 10(3):475-489.
• [26]Liu QR, Lu L, Zhu XG, Gong JP, Shaham Y, Uhl GR: Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res 2006, 1067(1):1-12.
• [27]Schmidt HD, Sangrey GR, Darnell SB, Schassburger RL, Cha JH, Pierce RC, Sadri-Vakili G: Increased brain-derived neurotrophic factor (BDNF) expression in the ventral tegmental area during cocaine abstinence is associated with increased histone acetylation at BDNF exon I-containing promoters. J Neurochem 2011, 120(2):202-209.
• [28]Groth R, Aanonsen L: Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB, prevent inflammation-induced hyperalgesia. Pain 2002, 100(1–2):171-181.
• [29]Laughlin TM, Vanderah TW, Lashbrook J, Nichols ML, Ossipov M, Porreca F, Wilcox GL: Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 1997, 72(1–2):253-260.
• [30]Meng M, Zhao X, Dang Y, Ma J, Li L, Gu S: Region-specific expression of brain-derived neurotrophic factor splice variants in morphine conditioned place preference in mice. Brain Res 2013, 1519:53-62.
• [31]Rozisky JR, Laste G, de Macedo IC, Santos VS, Krolow R, Noschang C, Vanzella C, Bertoldi K, Lovatel GA, de Souza IC, Siqueira IR, Dalmaz C, Caumo W, Torres IL: Neonatal morphine administration leads to changes in hippocampal BDNF levels and antioxidant enzyme activity in the adult life of rats. Neurochem Res 2013, 38(3):494-503.
• [32]Wang WS, Kang S, Liu WT, Li M, Liu Y, Yu C, Chen J, Chi ZQ, He L, Liu JG: Extinction of aversive memories associated with morphine withdrawal requires ERK-mediated epigenetic regulation of brain-derived neurotrophic factor transcription in the rat ventromedial prefrontal cortex. J Neurosci 2012, 32(40):13763-13775.
• [33]Ferrini F, Trang T, Mattioli TA, Laffray S, Del’Guidice T, Lorenzo LE, Castonguay A, Doyon N, Zhang W, Godin AG, Mohr D, Beggs S, Vandal K, Beaulieu JM, Cahill CM, Salter MW, De Koninck Y: Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl(-) homeostasis. Nat Neurosci 2013, 16(2):183-192.
• [34]Wen YR, Tan PH, Cheng JK, Liu YC, Ji RR: Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. J Formos Med Assoc 2011, 110(8):487-494.
• [35]Sakata K, Woo NH, Martinowich K, Greene JS, Schloesser RJ, Shen L, Lu B: Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc Natl Acad Sci U S A 2009, 106(14):5942-5947.
• [36]Li CQ, Xu JM, Liu D, Zhang JY, Dai RP: Brain derived neurotrophic factor (BDNF) contributes to the pain hypersensitivity following surgical incision in the rats. Mol Pain 2008, 4:27. BioMed Central Full Text
• [37]Slack SE, Grist J, Mac Q, McMahon SB, Pezet S: TrkB expression and phospho-ERK activation by brain-derived neurotrophic factor in rat spinothalamic tract neurons. J Comp Neurol 2005, 489(1):59-68.
• [38]Lai J, Luo MC, Chen Q, Ma S, Gardell LR, Ossipov MH, Porreca F: Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci 2006, 9(12):1534-1540.
• [39]Wollemann M, Benyhe S: Non-opioid actions of opioid peptides. Life Sci 2004, 75(3):257-270.
• [40]Sardella TC, Polgar E, Garzillo F, Furuta T, Kaneko T, Watanabe M, Todd AJ: Dynorphin is expressed primarily by GABAergic neurons that contain galanin in the rat dorsal horn. Mol Pain 2011, 7:76. BioMed Central Full Text
• [41]Ossipov MH, Bazov I, Gardell LR, Kowal J, Yakovleva T, Usynin I, Ekstrom TJ, Porreca F, Bakalkin G: Control of chronic pain by the ubiquitin proteasome system in the spinal cord. J Neurosci 2007, 27(31):8226-8237.
• [42]Shimoyama M, Tatsuoka H, Ohtori S, Tanaka K, Shimoyama N: Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain. Pain 2005, 114(1–2):221-230.
• [43]Luo MC, Chen Q, Ossipov MH, Rankin DR, Porreca F, Lai J: Spinal dynorphin and bradykinin receptors maintain inflammatory hyperalgesia. J Pain 2008, 9(12):1096-1105.
• [44]Parra MC, Nguyen TN, Hurley RW, Hammond DL: Persistent inflammatory nociception increases levels of dynorphin 1–17 in the spinal cord, but not in supraspinal nuclei involved in pain modulation. J Pain 2002, 3(4):330-336.
• [45]D’Addario C, Caputi FF, Ekstrom TJ, Di Benedetto M, Maccarrone M, Romualdi P, Candeletti S: Ethanol induces epigenetic modulation of prodynorphin and pronociceptin gene expression in the rat amygdala complex. J Mol Neurosci 2013, 49(2):312-319.
• [46]Liang D, Li X, Lighthall G, Clark JD: Heme oxygenase type 2 modulates behavioral and molecular changes during chronic exposure to morphine. Neuroscience 2003, 121(4):999-1005.
• [47]Rivat C, Vera-Portocarrero LP, Ibrahim MM, Mata HP, Stagg NJ, De Felice M, Porreca F, Malan TP: Spinal NK-1 receptor-expressing neurons and descending pathways support fentanyl-induced pain hypersensitivity in a rat model of postoperative pain. Eur J Neurosci 2009, 29(4):727-737.
• [48]Sahbaie P, Shi X, Li X, Liang D, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, David Clark J: Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice. J Pain 2012, 13(10):997-1007.
• [49]Uchida H, Matsushita Y, Ueda H: Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: implications in the development of neuropathic pain. Neuroscience 2013, 240:147-154.
• [50]Cazorla M, Premont J, Mann A, Girard N, Kellendonk C, Rognan D: Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 2011, 121(5):1846-1857.
• [51]Takemori AE, Ho BY, Naeseth JS, Portoghese PS: Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 1988, 246(1):255-258.
• [52]Tokuyama S, Nagae R, Mashida E, Hamabe W: Involvement of kappa opioid receptors in formalin-induced inhibition of analgesic tolerance to morphine in mice. J Pharm Pharmacol 2007, 59(8):1109-1115.
• [53]Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53(1):55-63.
• [54]Poree LR, Guo TZ, Kingery WS, Maze M: The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2-adrenoceptors. Anesth Analg 1998, 87(4):941-948.
• [55]Sun Y, Sahbaie P, Liang DY, Li WW, Li XQ, Shi XY, Clark JD: Epigenetic regulation of spinal CXCR2 signaling in incisional hypersensitivity in mice. Anesthesiology 2013, 119(5):1198-1208.